PBLA

Panbela Therapeutics, Inc. Common Stock

PBLA

Market cap $3.86M

Delisted

PBLA was delisted on the 6th of March, 2024.

Back to rankings

About: Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Employees: 7

Healthcare Drug Manufacturers - General

Financial journalist opinion

Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript

Panbela Therapeutics, Inc. (OTCQB:PBLA) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Operator Greetings, and welcome to the Panbela Therapeutics Third Quarter 2024 Earnings Call. At this time, all participants are on a listen-only mode and a question-and-answer will follow the formal presentation.

Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript

Panbela Provides Business Update and Reports Q3 2024 Financial Results

MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q3 2024 Financial Results

Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript

Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants James Carbonara - Hayden, IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics Second Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode.

Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript

Panbela Provides Business Update and Reports Q2 2024 Financial Results

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q2 2024 Financial Results

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024.

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The DSMB recommended study continuation without modification, marking the third consecutive positive safety review. The safety database now includes 395 patients, compared to 214 patients on November 29, 2023.

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript

Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants James Carbonara - IR, HaydenIR Jennifer Simpson - President & CEO Susan Horvath - CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics First Quarter 2024 Earnings Call. [Operator Instructions].

Panbela Provides Business Update and Reports Q1 2024 Financial Results

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q1 2024 Financial Results

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi.

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024.

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

See News Rankings

Charts implemented using Lightweight Charts™